ScholarIQanswers from OpenAlex

Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool

PaperCitations, authors & open-access status

Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool have?

ScholarIQcitation count

Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool has 173 citations in the OpenAlex counts ScholarIQ stores.

When was Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool published?

ScholarIQyear

Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool has 1998 year in the ScholarIQ index.

What is the open-access status of Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool?

ScholarIQoa status

Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool has closed oa status in the ScholarIQ index.

What is the DOI of Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool?

ScholarIQdoi

The DOI for Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool is on the source record.

What is the PMID of Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool?

ScholarIQpmid

The PMID for Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool is on the source record.

What is the OpenAlex record for Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool?

ScholarIQopenalex

The OpenAlex for Use of the Zung Self-Rating Depression Scale in cancer patients: Feasibility as a screening tool is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial